Kristen C Blanton1, Allison M Deal2, Kathleen A Kaiser-Rogers3, Carey K Anders4, Siobhan M O'Connor3, Johann D Hertel3, Benjamin C Calhoun5. 1. School of Medicine, University of North Carolina, Chapel Hill, NC, USA. 2. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 3. Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA. 4. Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA. 5. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ben.calhoun@unchealth.unc.edu.
Abstract
OBJECTIVE: Dual probe fluorescence in situ hybridization (FISH) assays for determination of human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer provide a ratio of HER2 to chromosome 17. The ratio may be skewed by copy number alterations (CNA) in the control locus for chromosome 17 (CEP17). We analyzed the impact of alternative chromosome 17 control probes on HER2 status in a series of breast cancers with an emphasis on patients reclassified as amplified. METHODS: Breast cancer patients with equivocal HER2 immunohistochemistry (2+) and equivocal FISH with CEP17 were included. Reclassification of HER2 status was assessed with alternative chromosome 17 control probes (LIS1 and RARA). RESULTS: A total of 40 unique patients with 46 specimens reflexed to alternative chromosome 17 probe testing were identified. The majority (>80%) of patients had pT1-2, hormone receptor-positive tumors with an intermediate or high combined histologic grade. There were 34/46 (73.9%) specimens reclassified as amplified with alternative probes, corresponding to 29/40 (72.5%) patients. Of the patients reclassified as amplified with alternative probes, 34.5% (10/29) received HER2-targeted therapy. CONCLUSION: In this series, the majority of breast cancers tested with alternative chromosome 17 control probes under the 2013 ASCO/CAP Guidelines were converted to HER2-amplified. The treatment data and the clinicopathologic profile of the tumors suggest that most of these patients will neither receive nor benefit from HER2-targeted therapy. The findings support the recommendation in the 2018 ASCO/CAP HER2 Guidelines to discontinue the use of alternative chromosome 17 probes.
OBJECTIVE: Dual probe fluorescence in situ hybridization (FISH) assays for determination of human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer provide a ratio of HER2 to chromosome 17. The ratio may be skewed by copy number alterations (CNA) in the control locus for chromosome 17 (CEP17). We analyzed the impact of alternative chromosome 17 control probes on HER2 status in a series of breast cancers with an emphasis on patients reclassified as amplified. METHODS:Breast cancerpatients with equivocal HER2 immunohistochemistry (2+) and equivocal FISH with CEP17 were included. Reclassification of HER2 status was assessed with alternative chromosome 17 control probes (LIS1 and RARA). RESULTS: A total of 40 unique patients with 46 specimens reflexed to alternative chromosome 17 probe testing were identified. The majority (>80%) of patients had pT1-2, hormone receptor-positive tumors with an intermediate or high combined histologic grade. There were 34/46 (73.9%) specimens reclassified as amplified with alternative probes, corresponding to 29/40 (72.5%) patients. Of the patients reclassified as amplified with alternative probes, 34.5% (10/29) received HER2-targeted therapy. CONCLUSION: In this series, the majority of breast cancers tested with alternative chromosome 17 control probes under the 2013 ASCO/CAP Guidelines were converted to HER2-amplified. The treatment data and the clinicopathologic profile of the tumors suggest that most of these patients will neither receive nor benefit from HER2-targeted therapy. The findings support the recommendation in the 2018 ASCO/CAP HER2 Guidelines to discontinue the use of alternative chromosome 17 probes.
Authors: Raymond R Tubbs; David G Hicks; James Cook; Erinn Downs-Kelly; James Pettay; Mary Beth Hartke; Lashonda Hood; Rosemary Neelon; Jonathan Myles; George Thomas Budd; Halle C Moore; Steve Andresen; Joseph P Crowe Journal: Diagn Mol Pathol Date: 2007-12
Authors: Gillian C Bethune; Daniel Veldhuijzen van Zanten; Rebecca F MacIntosh; Daniel Rayson; Tallal Younis; Kara Thompson; Penny J Barnes Journal: Histopathology Date: 2015-06-09 Impact factor: 5.087
Authors: Mithun Vinod Shah; Anne E Wiktor; Reid G Meyer; Kathleen S Tenner; Karla V Ballman; Stefan J Green; William R Sukov; Rhett P Ketterling; Edith A Perez; Robert B Jenkins Journal: J Clin Oncol Date: 2016-10-10 Impact factor: 44.544
Authors: Rashmi K Murthy; Sherene Loi; Alicia Okines; Elisavet Paplomata; Erika Hamilton; Sara A Hurvitz; Nancy U Lin; Virginia Borges; Vandana Abramson; Carey Anders; Philippe L Bedard; Mafalda Oliveira; Erik Jakobsen; Thomas Bachelot; Shlomit S Shachar; Volkmar Müller; Sofia Braga; Francois P Duhoux; Richard Greil; David Cameron; Lisa A Carey; Giuseppe Curigliano; Karen Gelmon; Gabriel Hortobagyi; Ian Krop; Sibylle Loibl; Mark Pegram; Dennis Slamon; M Corinna Palanca-Wessels; Luke Walker; Wentao Feng; Eric P Winer Journal: N Engl J Med Date: 2019-12-11 Impact factor: 91.245
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Neelam V Desai; Vanda Torous; Joel Parker; James T Auman; Gary B Rosson; Cassandra Cruz; Charles M Perou; Stuart J Schnitt; Nadine Tung Journal: Breast Cancer Res Date: 2018-07-11 Impact factor: 6.466